Clinical Trial: Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT06898957) titled 'Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)' on March 21.

Brief Summary: The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.

Study Start Date: April 15

Study Type: INTERVENTIONAL

Condition: Small Cell Lung Cancer

Intervention: DRUG: YL201

YL201 will be administered as an IV infusion.

DRUG: Tarlatamab

Tarlatamab will be administered as an IV infusion.

DRUG: Atezolizumab

Atezolizumab will be administere...